Northwest Biotherapeutics (LTS:0K95) Cyclically Adjusted PB Ratio: (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0K95 Northwest Biotherapeutics Inc LTS:0K95
11 GF Score
Price £2.40
! 5 Warning Signs
View Full Analysis

What is Northwest Biotherapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Northwest Biotherapeutics  (LTS:0K95) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Northwest Biotherapeutics Cyclically Adjusted PB Ratio Related Terms


Northwest Biotherapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Northwest Biotherapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Northwest Biotherapeutics Cyclically Adjusted PB Ratio Chart

Northwest Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Northwest Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LTS:0K95 vs FATE, IMRX, FHTX: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Northwest Biotherapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Northwest Biotherapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Northwest Biotherapeutics's Cyclically Adjusted PB Ratio falls into.


LTS:0K95
11GF Score
Northwest Biotherapeutics Inc LTS:0K95
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Northwest Biotherapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Northwest Biotherapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Northwest Biotherapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.024/330.2130*330.2130
=-0.024

Current CPI (Mar. 2026) = 330.2130.

Northwest Biotherapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 -0.126 241.018 -0.173
201609 -0.032 241.428 -0.044
201612 -0.135 241.432 -0.185
201703 -0.160 243.801 -0.217
201706 -0.116 244.955 -0.156
201709 -0.104 246.819 -0.139
201712 -0.153 246.524 -0.205
201803 -0.140 249.554 -0.185
201806 -0.143 251.989 -0.187
201809 -0.071 252.439 -0.093
201812 -0.071 251.233 -0.093
201903 -0.083 254.202 -0.108
201906 -0.074 256.143 -0.095
201909 -0.076 256.759 -0.098
201912 -0.056 256.974 -0.072
202003 -0.043 258.115 -0.055
202006 -0.090 257.797 -0.115
202009 -0.210 260.280 -0.266
202012 -0.325 260.474 -0.412
202103 -0.302 264.877 -0.376
202106 -0.291 271.696 -0.354
202109 -0.246 274.310 -0.296
202112 -0.098 278.802 -0.116
202203 -0.094 287.504 -0.108
202206 -0.072 296.311 -0.080
202209 -0.091 296.808 -0.101
202212 -0.098 296.797 -0.109
202303 -0.043 301.836 -0.047
202306 -0.043 305.109 -0.047
202309 -0.046 307.789 -0.049
202312 -0.044 306.746 -0.047
202403 -0.048 312.332 -0.051
202406 -0.049 314.175 -0.052
202409 -0.047 315.301 -0.049
202412 -0.056 315.605 -0.059
202503 -0.055 319.799 -0.057
202506 -0.051 322.561 -0.052
202509 -0.053 324.800 -0.054
202512 -0.029 324.054 -0.030
202603 -0.024 330.213 -0.024

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Northwest Biotherapeutics Business Description

Other Exchanges NWBO:USANBYB:Germany
Address 4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814
Northwest Biotherapeutics Inc a biotechnology company focused on developing personalized immune therapies for cancer. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S Food and Drug Administration.
11GF Score

Get the complete analysis for LTS:0K95

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£2.40
Price